Skip to main content

Table 5 C-statistic for distinguishing clinically significant disease based on GS

From: A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer

CI-PCa vs CS-PCa (GS) C-statistic
PSA 0.729
ProCUrE 0.684
Combined 0.775*
  1. C-statistics was used to determine any additive value of ProCUrE to PSA for discriminating CI-PCa vs CS-PCa as determined by GS in the training cohort. Only GS risk was analyzed since CAPRA score and D’Amico criteria is calculated using PSA. DeLong’s test *p = 0.039